Goldman Sachs’s Enliven Therapeutics ELVN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.8M | Sell |
189,505
-22,247
| -11% | -$446K | ﹤0.01% | 3003 |
|
|
2025
Q1 | $4.17M | Buy |
211,752
+80,506
| +61% | +$1.58M | ﹤0.01% | 2884 |
|
|
2024
Q4 | $2.95M | Buy |
131,246
+9,461
| +8% | +$213K | ﹤0.01% | 3236 |
|
|
2024
Q3 | $3.11M | Buy |
121,785
+56,032
| +85% | +$1.43M | ﹤0.01% | 3067 |
|
|
2024
Q2 | $1.54M | Buy |
65,753
+48,480
| +281% | +$1.13M | ﹤0.01% | 3350 |
|
|
2024
Q1 | $304K | Sell |
17,273
-5,425
| -24% | -$95.4K | ﹤0.01% | 4192 |
|
|
2023
Q4 | $314K | Buy |
22,698
+5,008
| +28% | +$69.3K | ﹤0.01% | 4162 |
|
|
2023
Q3 | $242K | Sell |
17,690
-9,596
| -35% | -$131K | ﹤0.01% | 4189 |
|
|
2023
Q2 | $557K | Sell |
27,286
-14,125
| -34% | -$288K | ﹤0.01% | 3923 |
|
|
2023
Q1 | $907K | Buy |
+41,411
| New | +$907K | ﹤0.01% | 3719 |
|
|
2022
Q3 | – | Sell |
-872,581
| Closed | -$1.07M | – | 5521 |
|
|
2022
Q2 | $1.07M | Buy |
872,581
+39,007
| +5% | +$47.6K | ﹤0.01% | 3899 |
|
|
2022
Q1 | $1.57M | Sell |
833,574
-10,174
| -1% | -$19.1K | ﹤0.01% | 3752 |
|
|
2021
Q4 | $1.9M | Buy |
843,748
+805,786
| +2,123% | +$1.81M | ﹤0.01% | 3539 |
|
|
2021
Q3 | $155K | Buy |
37,962
+27,416
| +260% | +$112K | ﹤0.01% | 4954 |
|
|
2021
Q2 | $83K | Sell |
10,546
-2,198
| -17% | -$17.3K | ﹤0.01% | 5156 |
|
|
2021
Q1 | $108K | Buy |
+12,744
| New | +$108K | ﹤0.01% | 5018 |
|
|
2020
Q2 | – | Sell |
-48,000
| Closed | -$769K | – | 4402 |
|
|
2020
Q1 | $769K | Buy |
+48,000
| New | +$769K | ﹤0.01% | 3257 |
|